Pharming PHAR
NASDAQ PHAR
$9.99 -0.02 (-0.20%)
At close: Sep 30, 2026 · 4:00 PM EDT

Pharming (PHAR) Equity Income (2022 - 2026)

Updated

Pharming's Equity Income was -$168,000 in Q2 2026, compared with -$429,000 a year earlier.

Analysis

Pharming (PHAR) Equity Income (2022 - 2026) Analysis & Trends

On a trailing twelve-month basis, Pharming's Equity Income was -$4.37 million through Jun 30, 2026; for FY2025, it was $623,000.

  • Equity Income shows a five-year compound annual growth rate of 11.5% (FY2020 to FY2025).
  • In earlier years, Equity Income was -$1.76 million in FY2024, -$289,000 in FY2023, -$1.08 million in FY2022 and $694,000 in FY2021 (+91.7%).
  • The Q2 2026 figure marks the highest quarterly Equity Income since Q3 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Equity Income (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn -
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn -
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn -
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn -2.00 Mn
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn -10.00 Mn
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn -
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn -
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn -
10 Pharming 702.38 Mn -127.78 Mn 141.47 Mn -168,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -168,000.00
Dec 31, 2025 -739,000.00
Jun 30, 2025 -429,000.00
Dec 31, 2024 -3.04 Mn
Sep 30, 2024 442,000.00
Dec 31, 2023 289,000.00
Sep 30, 2023 485,000.00
Dec 31, 2022 1.08 Mn
API Access

Pharming Equity Income API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=equity-income&ticker=PHAR&period=max&api_key=YOUR_API_KEY